Sitryx
Biotechnology ResearchEngland, United Kingdom11-50 Employees
Sitryx is a biopharmaceutical company focused on regulating cellular metabolism to develop disease-modifying therapies for autoimmune and inflammatory conditions, including immuno-oncology and immuno-inflammation. Its work centers on creating first-in-class oral therapies that aim to restore immune balance, with programs at multiple stages of drug discovery and a lead candidate progressing toward regulatory non-clinical studies to support a clinical trial authorization. The company seeks to address unmet needs in chronic immune-related diseases by targeting metabolic pathways involved in immune cell function. Based in Oxford, United Kingdom, Sitryx operates within the biotechnology research sector and has established a presence in the international biotech community through collaborations and partnerships, including notable activity with larger pharmaceutical players. The organization emphasizes a scientific leadership drawn from a team of researchers with expertise in immunometabolism and has grown its pipeline through ongoing development and exploration of metabolic targets such as glutaminase-1 and PKM2, with recent attention toward inflammatory skin diseases as part of its preclinical program development.
1-888-653-2347 
support@leadiq.com 
